leadf
logo-loader
viewOrthocell Ltd
(
ASX:OCC
)

Orthocell thrilled with positive nerve regeneration results

Orthocell Ltd's (ASX:OCC) Paul Anderson discusses with Proactive positive nerve regeneration results one year on from a study testing its nerve repair candidate on quadriplegic patients. The regenerative medicine company conducted the first interim data readout of all patients in the CelGro® clinical trial 12 months after the study concluded. 25 out of 33, or 75.8%, of all nerve repairs that took place during the study resulted in functional recovery.

Quick facts: Orthocell Ltd

Follow
ASX:OCC

Price: 0.51 AUD

Market Cap: $97.68 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Orthocell looks ahead to results from OrthoATI shoulder tendon study in Q4

Orthocell Ltd (ASX:OCC)'s Paul Anderson tells Proactive they've has passed a key milestone by completing the 12-month follow-up of the last patient treated in the Autologous Tenocyte Injection (OrthoATI®) rotator cuff tendon study. The RC study was designed to assess the effectiveness of...

3 weeks, 2 days ago

2 min read